Evidence and Guidance of Hepatitis C Therapy in Pregnancy – AJOG MFM
American Journal of Obstetrics and Gynecology MFM – AJOG MFM shared a post on LinkedIn:
“Hepatitis C remains a massive public health problem, but promise has arrived in direct-acting antivirals (DAAs).
In this review, the authors review the state of the evidence regarding hepatitis C therapy in pregnancy, arriving at a conclusion that while larger prospective trials are being conducted, shared-decision making for HepC therapy in pregnancy should be considered given the potential for pregnancy as a major window to combatting this infection. They also provide guidance on counseling about therapy, open registries, and ongoing trials.”
Title: Hepatitis C Treatment During Pregnancy: Time for a Practice Change
Authors: Karley Dutra, Jonathan M. Fenkel

Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Feb 24, 2026, 09:49Christopher Robinson: Does Aspirin Prophylaxis Prevent Preterm Preeclampsia?
-
Feb 24, 2026, 09:00Oral GnRH-Ant Elagolix to Patients With Surgically Diagnosed Endometriosis – RBMO
-
Feb 24, 2026, 06:35Adrian Hernandez Lopez on Comprehensive Pregnancy Care – AJOG MFM
-
Feb 24, 2026, 06:24Christopher Robinson: Postpartum Algorithm for Suspected Pulmonary Embolism
-
Feb 24, 2026, 04:48Beata Blazkova: Progress and Challenges of AI Adoption in Czech Healthcare
-
Feb 24, 2026, 04:23Christine McCullum-Gomez: Intergenerational Effects of Toxic Exposure on Health Uncovered
-
Feb 24, 2026, 01:21Barbara Lawrenz: IVF/ICSI Treatment May Not Only Be a Blessing but Also a Dilemma
-
Feb 24, 2026, 01:07Verena Ehrbar: ESHRE SIG Psychology Calls for Young Professionals
-
Feb 24, 2026, 00:57Beata Blazkova: Would You Treat a 0.03 Difference as Decisive in Embryo Selection?
